ImmunityBio Shares Gain After Bladder-Cancer Treatment Receives Recommendation From European Medicines Agency

Dow Jones12-12 19:47

By Connor Hart

Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder cancer in the European Union.

The stock rose 4.6%, to $2.29, in premarket trading Friday. Through Thursday's close, shares have lost about 30% of their value over the past year.

The biotechnology company said the recommendation is based on a review of a recent clinical trial, in which signs of cancer disappeared for more than 70% of patients receiving the treatment, called Anktiva.

The recommendation will help facilitate early access to medicines that address conditions where the remaining treatment option is surgery to remove the bladder, ImmunityBio said.

"Hundreds of patients in the U.S. are already experiencing the benefits of this therapy, and our goal is to make it available to patients in Europe and other parts of the world as quickly and responsibly as possible," said Patrick Soon-Shiong, ImmunityBio's global chief scientific and medical officer.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

December 12, 2025 06:47 ET (11:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590503736?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590503736","market":"sg","top_or_hot":-1,"title":"ImmunityBio Shares Gain After Bladder-Cancer Treatment Receives Recommendation From European Medicines Agency","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder cancer in the European Union. \n</p>\n<p>\n  The stock rose 4.6%, to $2.29, in premarket trading Friday. Through Thursday's close, shares have lost about 30% of their value over the past year. \n</p>\n<p>\n  The biotechnology company said the recommendation is based on a review of a recent clinical trial, in which signs of cancer disappeared for more than 70% of patients receiving the treatment, called Anktiva. \n</p>\n<p>\n  The recommendation will help facilitate early access to medicines that address conditions where the remaining treatment option is surgery to remove the bladder, ImmunityBio said. \n</p>\n<p>\n  \"Hundreds of patients in the U.S. are already experiencing the benefits of this therapy, and our goal is to make it available to patients in Europe and other parts of the world as quickly and responsibly as possible,\" said Patrick Soon-Shiong, ImmunityBio's global chief scientific and medical officer. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2025 06:47 ET (11:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Shares Gain After Bladder-Cancer Treatment Receives Recommendation From European Medicines Agency</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Shares Gain After Bladder-Cancer Treatment Receives Recommendation From European Medicines Agency\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-12 19:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder cancer in the European Union. \n</p>\n<p>\n  The stock rose 4.6%, to $2.29, in premarket trading Friday. Through Thursday's close, shares have lost about 30% of their value over the past year. \n</p>\n<p>\n  The biotechnology company said the recommendation is based on a review of a recent clinical trial, in which signs of cancer disappeared for more than 70% of patients receiving the treatment, called Anktiva. \n</p>\n<p>\n  The recommendation will help facilitate early access to medicines that address conditions where the remaining treatment option is surgery to remove the bladder, ImmunityBio said. \n</p>\n<p>\n  \"Hundreds of patients in the U.S. are already experiencing the benefits of this therapy, and our goal is to make it available to patients in Europe and other parts of the world as quickly and responsibly as possible,\" said Patrick Soon-Shiong, ImmunityBio's global chief scientific and medical officer. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 12, 2025 06:47 ET (11:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2590503736","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590503736","pubTimestamp":1765540020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder cancer in the European Union.The stock rose 4.6%, to $2.29, in premarket trading Friday. Through Thursday's close, shares have lost about 30% of their value over the past year.The biotechnology company said the recommendation is based on a review of a recent clinical trial, in which signs of cancer disappeared for more than 70% of patients receiving the treatment, called Anktiva.The recommendation will help facilitate early access to medicines that address conditions where the remaining treatment option is surgery to remove the bladder, ImmunityBio said.\"Hundreds of patients in the U.S. are already experiencing the benefits of this therapy, and our goal is to make it available to patients in Europe and other parts of the world as quickly and responsibly as possible,\" said Patrick Soon-Shiong","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc.","MDCO":"麦迪逊医药"},"translate_title":"膀胱癌治疗获得欧洲药品管理局推荐后，ImmunityBio股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9,"MDCO":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder cancer in the European Union. \n\n\n  The stock rose 4.6%, to $2.29, in premarket trading Friday. Through Thursday's close, shares have lost about 30% of their value over the past year. \n\n\n  The biotechnology company said the recommendation is based on a review of a recent clinical trial, in which signs of cancer disappeared for more than 70% of patients receiving the treatment, called Anktiva. \n\n\n  The recommendation will help facilitate early access to medicines that address conditions where the remaining treatment option is surgery to remove the bladder, ImmunityBio said. \n\n\n  \"Hundreds of patients in the U.S. are already experiencing the benefits of this therapy, and our goal is to make it available to patients in Europe and other parts of the world as quickly and responsibly as possible,\" said Patrick Soon-Shiong, ImmunityBio's global chief scientific and medical officer. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 06:47 ET (11:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590503736","isCrawlerRequest":true}